Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

Phase 2 Recruiting 75 enrolled University Hospital, Basel, Switzerland Clinical Trial Unit, University Hospital Basel, Switzerland · collab Swiss National Science Foundation · collab Wuerzburg University Hospital · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this investigator-initiated study is to assess the efficacy of treating patellofemoral osteoarthritis with an Advanced Therapy Medicinal Product (ATMP), autologous nasal chondrocyte tissue engineered cartilage (N-TEC), in comparison with a standard therapy using platelet rich plasma injections. The engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

Timeline

Start: 2024-06-06
Primary completion: 2028-09
Completion: 2029-09

Publications

Seitz S, Lehoczky G, Wixmerten A, Schuster-Amft C, Miot S, Shrestha K, Schaedelin S, Martin I, Mumme M. Treatment of patellofemoral osteoarthritis with nasal chondrocyte-based engineered cartilage implantation in a randomised, controlled, multicentre phase II clinical trial: protocol for a randomised controlled trial. BMJ Open. 2025 Aug 21;15(8):e106140. doi: 10.1136/bmjopen-2025-106140.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N-TEC	Unknown	—	Other
Comparator	Platelet Rich Plasma	Other / unclassified	5 ml	Other

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

Summary

Timeline

Publications

Drugs

Indications